Patulous Eustachian Tube and the Role of Compounded Estradiol (Estrogen) Nasal Spray
February 2026
Patulous Eustachian Tube (PET) is a frustrating and often quality-of-life–limiting disorder characterized by an abnormally patent Eustachian tube. Unlike obstructive Eustachian tube dysfunction—which is far more common and associated with middle ear effusion and infection—PET results from excessive tubal openness, leading to disturbing auditory symptoms without overt structural disease.
While no single therapy is universally effective, estrogen-based therapies have long been used to promote mucosal engorgement around the Eustachian tube orifice. Traditionally, conjugated estrogen nasal spray preparations such as Premarin® have been employed. However, compounded estradiol nasal spray offers a targeted, customizable, and ethically uncomplicated alternative that many ENT physicians may not be fully familiar with.
What Is Patulous Eustachian Tube?
PET occurs when the Eustachian tube remains abnormally open at rest. Common symptoms include:
- Aural fullness or pressure
- Autophony (hearing one’s own voice amplified or echoing)
- Audible respiration synchronized with breathing
A hallmark diagnostic feature is symptom relief when the patient places their head in a dependent position (e.g., head between the knees), which transiently increases venous engorgement of the peritubal tissues and narrows the lumen.
Etiology and Contributing Factors
The most frequently identified precipitating factor is rapid or significant weight loss, with reductions of as little as 10–20 pounds sufficient to decrease peritubal fat volume and support. Other proposed contributors include:
- Hormonal fluctuations (including estrogen deficiency states)
- Dehydration
- Chronic illness or catabolic states
- Idiopathic cases (a substantial proportion)
Importantly, PET is typically not associated with gross anatomic abnormalities of the Eustachian tube, though nasal endoscopy is often performed to rule out structural pathology.
Patulous Eustachian Tube Treatment Landscape
There is no gold-standard therapy for PET. Management is often symptom-driven and may include:
- Observation, as some cases resolve spontaneously
- Topical estrogen therapy to promote mucosal engorgement
- Potassium iodide drops
- Tympanostomy tubes, which may reduce autophony in select patients
- Surgical interventions, reserved for refractory cases due to variable outcomes
Among these, estrogen therapy remains one of the more consistently utilized non-surgical options.
Estrogen Therapy in PET: Mechanistic Rationale
Estrogen applied topically to the nasopharyngeal region is believed to:
- Increase local mucosal thickness
- Promote vascular engorgement of peritubal tissues
- Reduce the resting patency of the Eustachian tube
This localized effect is precisely what makes intranasal estrogen therapy attractive for PET management.
Premarin Nasal Spray: Limitations and Concerns
Premarin is a conjugated equine estrogen derived from the urine of pregnant horses. While historically used in PET management, it presents several challenges:
- Ethical concerns related to animal-derived sourcing
- Variable estrogen composition, as it contains multiple estrogenic compounds rather than a single active hormone
- Limited flexibility in concentration and formulation
- Availability and cost
These factors have driven interest in alternatives that offer greater control and transparency.
Compounded Estradiol Nasal Spray: A Targeted Alternative
Our compounded estradiol nasal spray is Estradiol 0.5mg/(0.1mL) Nasal Spray in MucoLox™. When prepared, this formulation offers several advantages:
Key Benefits:
- Single, well-characterized active ingredient
- Customizable concentration based on prescriber preference and patient response
- Targeted intranasal delivery, minimizing systemic exposure
- Non–animal-derived source, avoiding ethical concerns associated with equine estrogens
- Mucoadhesive properties that increase contact time at the site of action
Clinical Use Considerations
- Typically administered intranasally with instructions to direct spray toward the nasopharyngeal region. The force from the jet nozzle will irritate and engorge the tissues.
- Dosing frequency and duration are individualized
- Patients should be counseled regarding potential local irritation and theoretical systemic absorption, though systemic effects are generally minimal at low intranasal doses
- Document PET diagnosis on the prescription. Estradiol nasal solution is also used for epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT). However, it is dispensed to HHT patients in a dropper as the pressure from the spray bottle will exacerbate nosebleeds.
Safety and Regulatory Notes
As with all compounded medications:
- Estradiol nasal spray is not FDA-approved and is not reviewed by the FDA for safety or efficacy.
- It should be prescribed only when a patient-specific clinical need exists that cannot be met by a commercially available product.
- Collaboration with a reputable compounding pharmacy experienced in intranasal formulations is essential.
Practical Takeaway for ENT Physicians
For patients with symptomatic PET who do not respond to conservative measures—or who are seeking alternatives to Premarin—compounded estradiol nasal spray represents a rational, customizable option grounded in established physiologic principles.
While not curative and not universally effective, it offers ENT physicians another tool to address a condition that is often difficult to manage and deeply disruptive to patients’ daily lives.
To prescribe Estradiol 0.5mg/(0.1mL) Nasal Spray in MucoLox™ visit the Practitioner Portal to download a prescription blank.
To speak with a pharmacist, contact us at 833.540.3500.